| Kinsolving honored as 2007 Distinguished Alumnus | |
|
Richard Kinsolving, biology ’57, a pharmaceutical scientist who has revolutionized the treatment of allergy symptoms, has been named Tennessee Tech University’s 2007 Distinguished Alumnus. Presented by TTU’s Alumni Association, the Distinguished Alumnus award is one of the highest bestowed by the university and recognizes those who have demonstrated professional excellence and achievement. “The Tennessee Tech of the 1950s had a wisdom we could not appreciate at the time,” said Kinsolving. “We did not even know how much we did not know of the larger world — but Tech did — and changed us forever. Tech gave us an accelerated course in growing up along with technology.” Kinsolving, a scientist with Immune Recovery Foundation, conceived and designed the first of a new class of drugs — non-sedating antihistamines. Seldane, the first of this class in 1974, reached more than $2 billion in annual sales. Its sequel in 2001, Allegra, is still marketed. |
|
•Alumni News Kinsolving honored as 2007 Distinguished Alumnus Stack hits a home run with Colorado Rockies First registered nursing grad now international doctor Engineer-turned-artist reveals war with quiet images Fanning coordinates experiments on International Space Station |
|
|
During this time frame, Kinsolving was a director in several pharmaceutical companies, including Fisons Corp., Pennwalt, Merrell, and Warner-Lambert. A leading researcher since the 1960s, Kinsolving holds 16 other patents in the pharmaceutical industry. He was the founder and chief executive officer of several biotech companies, including Bestechnologies, BioPharmacon, Immuno- Rx, and the Immune Recovery Foundation, where he currently serves as chairman and chief research scientist. He is on the board of directors of Cel-Sci Corp., where he heads both the audit and executive compensation committees. During the past few years, Kinsolving has dedicated himself to researching the immunology of cancer and other chronic diseases. His efforts are focused on developing useful clinical applications for academic research findings and determining ways to integrate them into current medical practice. He shares his time among facilities in Atlanta, Mexico and Malta. Kinsolving also holds a master’s in physiology from Vanderbilt University and a doctorate in pharmacology from Emory University. (Spring 2008) |
|
 |